Coherus Oncology, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−12.76%
vs ±36.1% implied · ×0.35
shaded = implied · ▲▼ = realized
Coherus Oncology, Inc.
0.83
Coherus Oncology has 3 disclosed suppliers and 5 disclosed customers in SEC filings.
SentenceIn December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target PVRIG, including the antibody GSK4381562 (the "Licensed Antibodies").
SentenceOn February 4, 2026, we announced a clinical supply agreement with Janssen Research & Development, LLC, to evaluate tagmokitug in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer.
CHRS 10-Kaccession 0001104659-26-025308
SentenceJunshi Biosciences is responsible for supplying us with drug substance and final drug products.
CHRS 10-Kaccession 0001104659-26-025308
SentenceIntas has designated Accord to purchase the physical assets, including product inventory.
CHRS 10-Kaccession 0001104659-26-025308
SentenceOn June 27, 2024, we entered into a license Agreement with Apotex, pursuant to which, we granted to Apotex the Canada License Agreement.
CHRS 10-Kaccession 0001104659-26-025308
SentenceThe first such payment is payable by Intas to us if Net Sales of UDENYCA for four consecutive fiscal quarters from July 1, 2025 through September 30, 2026 are equal to or greater than $300 million, and the second such payment is payable by Intas to the Company if Net Sales of UDENYCA for four consecutive fiscal quarters from July 1, 2025 through March 31, 2027 are equal to or greater than $350 million.
CHRS 10-Kaccession 0001104659-26-025308
SentenceIn 2025, three wholesalers individually comprised approximately 43%, 36%, and 20%, respectively, of our total gross product revenue from continuing operations.
CHRS 10-Kaccession 0001104659-26-025308
Linked news
Expected move
No implied move.